WordNet
- the 3rd letter of the Roman alphabet (同)c
- (music) the keynote of the scale of C major
- a general-purpose programing language closely associated with the UNIX operating system
- the 9th letter of the Roman alphabet (同)i
PrepTutorEJDIC
- carbonの化学記号
- 『私は』私が
- iodineの化学記号
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/12/14 11:32:53」(JST)
[Wiki en表示]
APOC2 |
|
Available structures |
PDB |
Ortholog search: PDBe RCSB |
List of PDB id codes |
1SOH, 1BY6, 1I5J, 1O8T
|
|
|
Identifiers |
Aliases |
APOC2, APO-CII, APOC-II, apolipoprotein C2 |
External IDs |
OMIM: 608083 MGI: 88054 HomoloGene: 47928 GeneCards: APOC2 |
Gene ontology |
Molecular function |
• lipase inhibitor activity
• phospholipase binding
• protein homodimerization activity
• lipoprotein lipase activator activity
• phospholipase activator activity
• enzyme activator activity
• lipid binding
|
Cellular component |
• chylomicron
• very-low-density lipoprotein particle
• spherical high-density lipoprotein particle
• extracellular fluid
• extracellular region
• early endosome
• low-density lipoprotein particle
• high-density lipoprotein particle
• extracellular exosome
• intermediate-density lipoprotein particle
|
Biological process |
• high-density lipoprotein particle clearance
• lipoprotein metabolic process
• lipid transport
• positive regulation of triglyceride catabolic process
• chylomicron remnant clearance
• lipid metabolic process
• phospholipid efflux
• positive regulation of lipoprotein lipase activity
• positive regulation of fatty acid biosynthetic process
• negative regulation of very-low-density lipoprotein particle clearance
• retinoid metabolic process
• negative regulation of receptor-mediated endocytosis
• lipid catabolic process
• positive regulation of phospholipase activity
• positive regulation of phospholipid catabolic process
• cholesterol efflux
• transport
• chylomicron remodeling
• very-low-density lipoprotein particle remodeling
• negative regulation of cholesterol transport
• cholesterol homeostasis
• positive regulation of very-low-density lipoprotein particle remodeling
• triglyceride-rich lipoprotein particle remodeling
• triglyceride homeostasis
• negative regulation of lipid metabolic process
• reverse cholesterol transport
• negative regulation of catalytic activity
• positive regulation of catalytic activity
|
Sources:Amigo / QuickGO |
|
Orthologs |
Species |
Human |
Mouse |
Entrez |
|
|
Ensembl |
|
|
UniProt |
|
|
RefSeq (mRNA) |
|
|
NM_001277944
NM_001309795
|
|
RefSeq (protein) |
|
|
NP_001264873.1
NP_001296724.1
NP_001296728.1
|
|
Location (UCSC) |
Chr 19: 44.94 – 44.95 Mb |
Chr 7: 19.67 – 19.68 Mb |
PubMed search |
[1] |
[2] |
Wikidata |
View/Edit Human |
View/Edit Mouse |
Apo-CII |
nmr structure of human apolipoprotein c-ii in the presence of sds
|
Identifiers |
Symbol |
Apo-CII |
Pfam |
PF05355 |
InterPro |
IPR008019 |
SCOP |
1by6 |
SUPERFAMILY |
1by6 |
Available protein structures: |
Pfam |
structures |
PDB |
RCSB PDB; PDBe; PDBj |
PDBsum |
structure summary |
|
Apolipoprotein C2 or apolipoprotein C-II is a protein that in humans is encoded by the APOC2 gene.
The protein encoded by this gene is secreted in plasma where it is a component of very low density lipoproteins and chylomicrons. This protein activates the enzyme lipoprotein lipase in capillaries,[3] which hydrolyzes triglycerides and thus provides free fatty acids for cells. Mutations in this gene cause hyperlipoproteinemia type IB, characterized by xanthomas, pancreatitis, and hepatosplenomegaly, but no increased risk for atherosclerosis. Lab tests will show elevated blood levels of triglycerides, cholesterol, and chylomicrons[4]
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
[[File:
|px|alt=Statin Pathway edit]]
File:StatinPathway_WP430.png
Statin Pathway edit
- ^ The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".
See also
References
- ^ "Human PubMed Reference:".
- ^ "Mouse PubMed Reference:".
- ^ Kim SY, Park SM, Lee ST (2006). "Apolipoprotein C-II is a novel substrate for matrix metalloproteinases". Biochem. Biophys. Res. Commun. 339 (1): 47–54. doi:10.1016/j.bbrc.2005.10.182. PMID 16314153.
- ^ "Entrez Gene: APOC2 apolipoprotein C-II".
- Jackson RL, Baker HN, Gilliam EB, Gotto AM (1977). "Primary structure of very low density apolipoprotein C-II of human plasma.". Proc. Natl. Acad. Sci. U.S.A. 74 (5): 1942–5. doi:10.1073/pnas.74.5.1942. PMC 431048. PMID 194244.
- Lycksell PO, Ohman A, Bengtsson-Olivecrona G, et al. (1992). "Sequence specific 1H-NMR assignments and secondary structure of a carboxy-terminal functional fragment of apolipoprotein CII.". Eur. J. Biochem. 205 (1): 223–31. doi:10.1111/j.1432-1033.1992.tb16772.x. PMID 1555583.
- Hegele RA, Connelly PW, Maguire GF, et al. (1992). "An apolipoprotein CII mutation, CIILys19----Thr' identified in patients with hyperlipidemia.". Dis. Markers. 9 (2): 73–80. PMID 1782747.
- Crecchio C, Capurso A, Pepe G (1990). "Identification of the mutation responsible for a case of plasmatic apolipoprotein CII deficiency (Apo CII-Bari).". Biochem. Biophys. Res. Commun. 168 (3): 1118–27. doi:10.1016/0006-291X(90)91145-I. PMID 1971748.
- Bengtsson-Olivecrona G, Sletten K (1990). "Primary structure of the bovine analogues to human apolipoproteins CII and CIII. Studies on isoforms and evidence for proteolytic processing.". Eur. J. Biochem. 192 (2): 515–21. doi:10.1111/j.1432-1033.1990.tb19255.x. PMID 2209608.
- Wei CF, Tsao YK, Robberson DL, et al. (1986). "The structure of the human apolipoprotein C-II gene. Electron microscopic analysis of RNA:DNA hybrids, complete nucleotide sequence, and identification of 5' homologous sequences among apolipoprotein genes.". J. Biol. Chem. 260 (28): 15211–21. PMID 2415514.
- Fojo SS, Lohse P, Parrott C, et al. (1989). "A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.". J. Clin. Invest. 84 (4): 1215–9. doi:10.1172/JCI114287. PMC 329780. PMID 2477392.
- Jackson CL, Bruns GA, Breslow JL (1986). "Isolation of cDNA and genomic clones for apolipoprotein C-II". Meth. Enzymol. Methods in Enzymology. 128: 788–800. doi:10.1016/0076-6879(86)28106-9. ISBN 9780121820282. PMID 3014272.
- Fojo SS, Law SW, Brewer HB (1987). "The human preproapolipoprotein C-II gene. Complete nucleic acid sequence and genomic organization". FEBS Lett. 213 (1): 221–6. doi:10.1016/0014-5793(87)81495-3. PMID 3030808.
- Fojo SS, Stalenhoef AF, Marr K, et al. (1989). "A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a deficiency of apolipoprotein C-II". J. Biol. Chem. 263 (34): 17913–6. PMID 3192518.
- Fojo SS, Beisiegel U, Beil U, et al. (1988). "Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency". J. Clin. Invest. 82 (5): 1489–94. doi:10.1172/JCI113756. PMC 442713. PMID 3263393.
- Connelly PW, Maguire GF, Hofmann T, Little JA (1987). "Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein". Proc. Natl. Acad. Sci. U.S.A. 84 (1): 270–3. doi:10.1073/pnas.84.1.270. PMC 304185. PMID 3467353.
- Fairwell T, Hospattankar AV, Brewer HB, Khan SA (1987). "Human plasma apolipoprotein C-II: total solid-phase synthesis and chemical and biological characterization". Proc. Natl. Acad. Sci. U.S.A. 84 (14): 4796–800. doi:10.1073/pnas.84.14.4796. PMC 305192. PMID 3474626.
- Fojo SS, Taam L, Fairwell T, et al. (1986). "Human preproapolipoprotein C-II. Analysis of major plasma isoforms". J. Biol. Chem. 261 (21): 9591–4. PMID 3525527.
- Das HK, Jackson CL, Miller DA, et al. (1987). "The human apolipoprotein C-II gene sequence contains a novel chromosome 19-specific minisatellite in its third intron". J. Biol. Chem. 262 (10): 4787–93. PMID 3558370.
- Connelly PW, Maguire GF, Little JA (1988). "Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease". J. Clin. Invest. 80 (6): 1597–606. doi:10.1172/JCI113246. PMC 442428. PMID 3680515.
- Baggio G, Manzato E, Gabelli C, et al. (1986). "Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients". J. Clin. Invest. 77 (2): 520–7. doi:10.1172/JCI112332. PMC 423374. PMID 3944267.
- Menzel HJ, Kane JP, Malloy MJ, Havel RJ (1986). "A variant primary structure of apolipoprotein C-II in individuals of African descent". J. Clin. Invest. 77 (2): 595–601. doi:10.1172/JCI112342. PMC 423392. PMID 3944271.
- Sharpe CR, Sidoli A, Shelley CS, et al. (1984). "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance". Nucleic Acids Res. 12 (9): 3917–32. doi:10.1093/nar/12.9.3917. PMC 318799. PMID 6328445.
- Jackson CL, Bruns GA, Breslow JL (1984). "Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII". Proc. Natl. Acad. Sci. U.S.A. 81 (10): 2945–9. doi:10.1073/pnas.81.10.2945. PMC 345197. PMID 6328478.
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
- Dallinga-Thie GM1,2, Kroon J3,4, Borén J5, Chapman MJ6.
- Current cardiology reports.Curr Cardiol Rep.2016 Jul;18(7):67. doi: 10.1007/s11886-016-0745-6.
- It is now evident that elevated circulating levels of triglycerides in the non-fasting state, a marker for triglyceride (TG)-rich remnant particles, are associated with increased risk of premature cardiovascular disease (CVD). Recent findings from basic and clinical studies have begun to elucidate t
- PMID 27216847
- Solution conditions affect the ability of K30D mutation to prevent amyloid fibril formation by apolipoprotein C-II: insights from experiments and theoretical simulations.
- Mao Y, Todorova N, Zlatic CO, Gooley PR, Griffin MD, Howlett GJ, Yarovsky I.
- Biochemistry.Biochemistry.2016 Jun 17. [Epub ahead of print]
- Apolipoproteins form amphipathic helical structures that bind lipid surfaces. Paradoxically, lipid-free apolipoproteins display a high propensity to form cross-β structure and self-associate into disease-related amyloid fibrils. Studies of apolipoprotein C-II (apoC-II) amyloid fibrils suggest that
- PMID 27311794
- Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII.
- Nasr SH1, Dasari S2, Hasadsri L1, Theis JD1, Vrana JA1, Gertz MA3, Muppa P1, Zimmermann MT2, Grogg KL1, Dispenzieri A4, Sethi S1, Highsmith WE Jr1, Merlini G5, Leung N3, Kurtin PJ6.
- Journal of the American Society of Nephrology : JASN.J Am Soc Nephrol.2016 Jun 13. pii: ASN.2015111228. [Epub ahead of print]
- Amyloidosis is characterized by extracellular deposition of misfolded proteins as insoluble fibrils. Most renal amyloidosis cases are Ig light chain, AA, or leukocyte chemotactic factor 2 amyloidosis, but rare hereditary forms can also involve the kidneys. Here, we describe the case of a 61-year-old
- PMID 27297947
Japanese Journal
- Apolipoprotein C-II Deficiency with No Rare Variant in the APOC2 Gene
- Takase Satoru,Osuga Jun-ichi,Fujita Hayato,Hara Kazuo,Sekiya Motohiro,Igarashi Masaki,Takanashi Mikio,Takeuchi Yoshinori,Izumida Yoshihiko,Ohta Keisuke,Kumagai Masayoshi,Nishi Makiko,Kubota Midori,Masuda Yukari,Taira Yoshino,Okazaki Sachiko,Iizuka Yoko,Yahagi Naoya,Ohashi Ken,Yoshida Hiroshi,Yanai Hidekatsu,Tada Norio,Gotoda Takanari,Ishibashi Shun,Kadowaki Takashi,Okazaki Hiroaki
- Journal of Atherosclerosis and Thrombosis 20(5), 481-493, 2013
- … Aim: Familial apolipoprotein C-II (apoC-II) deficiency is a rare autosomal recessive disorder with marked hypertriglyceridemia resulting from impaired activation of lipoprotein lipase. … In most cases of apoC-II deficiency, causative mutations have been found in the protein-coding region of APOC2; …
- NAID 130004444688
- Diagnosis and Management of Type I and Type V Hyperlipoproteinemia
- Gotoda Takanari,Shirai Koji,Ohta Takao,Kobayashi Junji,Yokoyama Shinji,Oikawa Shinichi,Bujo Hideaki,Ishibashi Shun,Arai Hidenori,Yamashita Shizuya,Harada-Shiba Mariko,Eto Masaaki,Hayashi Toshio,Sone Hirohito,Suzuki Hiroaki,Yamada Nobuhiro
- Journal of Atherosclerosis and Thrombosis 19(1), 1-12, 2012
- … Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. …
- NAID 130004721898
- Visualization of polymorphism in apolipoprotein C-II amyloid fibrils
- Teoh Chai L.,Yagi Hisashi,Griffin Michael D. W. [他],GOTO Yuji,HOWLETT Geoffrey J.
- The journal of biochemistry 149(1), 67-74, 2011-01-01
- NAID 10030582902
Related Links
- forum Join the Word of the Day Mailing List For webmasters TheFreeDictionary Google Bing? Word / Article Starts with Ends with Text ... apolipoprotein C-II, a protein component of chylomicrons and very-low-density lipoprotein that ...
- GoPubMed lists recent and important papers and reviews for apolipoprotein C-II(apolipoprotein C-II) ... [Therapeutic application of diacylglycerol oil for the metabolic syndrome]. Review Tada et al., Ichikawa, Japan. In Rinsho Byori, 2010
★リンクテーブル★
[★]
[★]
[★]
[★]
[★]
- 関
- apo
[★]
- 関
- apo C、apoC